Literature DB >> 33002281

Brain ischemic injury in COVID-19-infected patients: a series of 10 post-mortem cases.

Viscardo P Fabbri1,2, Maria P Foschini1,2, Tiziana Lazzarotto3,4, Liliana Gabrielli4, Giovanna Cenacchi1,5, Carmine Gallo2, Raffaele Aspide6, Guido Frascaroli7, Pietro Cortelli1,8, Mattia Riefolo3,5, Caterina Giannini1,9, Antonietta D'Errico3,5.   

Abstract

Entities:  

Year:  2020        PMID: 33002281      PMCID: PMC7536900          DOI: 10.1111/bpa.12901

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


× No keyword cloud information.
To the Editor: The coronavirus disease 2019 (COVID‐19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). COVID‐19 symptoms are not limited to the respiratory tract, but complications have been described involving other organs including brain. At present, data on SARS‐CoV‐2 neuropathological features are limited (4, 5, 8, 10) and most frequently focused on cases presenting neurological symptoms. We describe the CNS neuropathological findings detected in 10 individuals who died of SARS‐CoV‐2 related respiratory failure [lung histopathologic features of eight cases were reported by Damiani et al (2)] in absence of specific neurological symptoms. SARS‐CoV‐2 RNA was searched by real‐time PCR analysis in formalin‐fixed, paraffin‐embedded (FFPE) specimens. Detailed materials and methods, clinical data (Table 1) and neuropathological results (Table 2) are reported in the Supplementary files.
Table 1

clinical data. Abbreviations: M = male; F = female; ECMO = Extra‐Corporeal Membrane Oxygenation; BAL = Bronchoalveolar Lavage; PNX = pneumothorax; OB = obstructive bronchitis; MRSA = Methicillin‐resistant Staphylococcus aureus.

AgeGenderSymptoms duration before death (days)PM interval (hours)Associated pathologiesSymptomsOther
Case 1 51M631

Ictus cerebri (2006)

Hypertension

Glaucoma

Kidney failure

Drug abuser

Dyspnea

Fever

Dialysis

C. glabrata

Case 2 64M1672

Obesity

Hypertension

Dyspnea

Fever

Dialysis

Case 3 70F1338

Ictus cerebri (2015)

Obesity

Smoker

Dyspnea

Fever

Case 4 62M1436

Obesity

Hypertension

Dyspnea

Fever

Case 5 44M2629

Diabetes type I

Obesity

Hypertension

Dyspnea

ECMO

E. coli

Case 6 64F2550

Obesity

Crohn disease

Dyspnea

C. glabrata

Case 7 52M1655

Obesity

Hypertension

Dyspnea

Case 8 66M3525

Hypertension

Dyslipidemia

Fever

P. aeruginosa

S. aureus

C. albicans

S. capitis

Case 9 74M2624

Ischemic cardiomyopathy (previous acute myocardial infarction)

OB

Atrial fibrillation

Diabetes type II

Urinary retention (pelvic mass)

Fever

Syncope

Previous pneumonia (February)

During hospitalization, pneumonia SARS‐CoV2 related

MRSA

PNX

Case 10 62F1737

Hypothyroidism

Fever

Muscular weakness

S. aureus

Table 2

Summary of neuropathological findings. Abbreviations: OT = olfactory tract and bulb, B = brain, L = lungs.

Brain weight (g)Macroscopic findingsHistological findingsOT CoV‐2B CoV‐2L CoV‐2
Case 1 1480

Oedema

Left frontal lobe infarction

Meningeal congestion

Atherosclerosis

Global hypoxic‐ischemic injury

Small vessels ectasia, variable perivascular oedema, perivascular micro‐haemorrhages

Endovascular microthrombi

Microglial activation, especially in medulla oblongata

Glial scar consistent with previous frontal lobe infarct

recent microscopic cortical infarcts

Right pyramidal tract atrophy

Yes

Yes

Yes
Case 2 1670

Oedema

Right parietal lobe infarction

Meningeal congestion

Global hypoxic‐ischemic injury

Small vessels ectasia, variable perivascular oedema, perivascular micro‐haemorrhages

Endovascular microthrombi

Microglial activation, especially in medulla oblongata

Recent cerebral parietal infraction and microscopic cortical infarcts

NoNoYes
Case 3 1320

Oedema

Right frontal lobe infarction

Meningeal congestion

Global hypoxic‐ischemic injury

Small vessels ectasia, variable perivascular oedema, perivascular micro‐haemorrhages

Endovascular microthrombi

Sparse microglial activation, especially in medulla oblongata

Ancient frontal lobe infarction (glial scar) and recent microscopic infarcts

Left pyramidal tract atrophy

NoNoYes
Case 4 1870

Oedema

Meningeal congestion

Global hypoxic‐ischemic injury

Small vessels ectasia, variable perivascular oedema, perivascular micro‐haemorrhages

Endovascular microthrombi

Recent microscopic infarcts

Moderate meningeal chronic lymphocytic infiltration (composed of T‐lymphocytes, Cd3 and CD4 positive)

NoNoYes
Case 5 1870

Oedema

Uncal herniation

Meningeal congestion

Global hypoxic‐ischemic injury

Small vessels ectasia, variable perivascular oedema, perivascular micro‐haemorrhages

Endovascular microthrombi

Recent microscopic infarcts

NoNoYes
Case 6 1350

Oedema

Uncal herniation

Meningeal congestion

Global hypoxic‐ischemic injury

Small vessels ectasia, variable perivascular oedema, perivascular micro‐haemorrhages

Endovascular microthrombi

Recent microscopic infarcts

NoNoYes
Case 7 1650

Oedema

Meningeal congestion

Global hypoxic‐ischemic injury

Small vessels ectasia, variable perivascular oedema, perivascular micro‐haemorrhages

Endovascular microthrombi

Recent microscopic infarcts

Sparse microglial activation, especially in medulla oblongata

NoNoYes
Case 8 1300

Oedema

Meningeal congestion

Meningeal purulent accumulation

Global hypoxic‐ischemic injury

Small vessels ectasia, variable perivascular oedema, perivascular micro‐haemorrhages

Endovascular microthrombi

Recent microscopic infarcts

Microglial activation, especially in medulla oblongata

Initial feature of Acute purulent meningitis

NoNoYes
Case 9 1490

Oedema

Meningeal congestion with focal blood extravasation

Atherosclerosis

Global hypoxic‐ischemic injury

Small vessels ectasia, variable perivascular oedema, perivascular micro‐haemorrhages

Endovascular microthrombi

Focal leptomeningeal haemorrhage

Recent parieto‐occipital lobe infarction and microscopic infarcts.

Spinal cord Schwannoma

No (brain and spinal cord)NoYes
Case 10 1350

Oedema

Meningeal congestion

Global hypoxic‐ischemic injury

Small vessels ectasia, variable perivascular oedema, perivascular micro‐haemorrhages

Endovascular microthrombi

Recent microscopic infarcts, the largest in the para‐hippocampal region

No (brain and spinal cord)NoYes
clinical data. Abbreviations: M = male; F = female; ECMO = Extra‐Corporeal Membrane Oxygenation; BAL = Bronchoalveolar Lavage; PNX = pneumothorax; OB = obstructive bronchitis; MRSA = Methicillin‐resistant Staphylococcus aureus. Ictus cerebri (2006) Hypertension Glaucoma Kidney failure Drug abuser Dyspnea Fever Dialysis C. glabrata Obesity Hypertension Dyspnea Fever Dialysis Ictus cerebri (2015) Obesity Smoker Dyspnea Fever Obesity Hypertension Dyspnea Fever Diabetes type I Obesity Hypertension Dyspnea ECMO E. coli Obesity Crohn disease Dyspnea C. glabrata Obesity Hypertension Dyspnea Hypertension Dyslipidemia Fever P. aeruginosa S. aureus C. albicans S. capitis Ischemic cardiomyopathy (previous acute myocardial infarction) OB Atrial fibrillation Diabetes type II Urinary retention (pelvic mass) Fever Syncope Previous pneumonia (February) During hospitalization, pneumonia SARS‐CoV2 related MRSA PNX Hypothyroidism Fever Muscular weakness S. aureus Summary of neuropathological findings. Abbreviations: OT = olfactory tract and bulb, B = brain, L = lungs. Oedema Left frontal lobe infarction Meningeal congestion Atherosclerosis Global hypoxic‐ischemic injury Small vessels ectasia, variable perivascular oedema, perivascular micro‐haemorrhages Endovascular microthrombi Microglial activation, especially in medulla oblongata Glial scar consistent with previous frontal lobe infarct recent microscopic cortical infarcts Right pyramidal tract atrophy Yes Oedema Right parietal lobe infarction Meningeal congestion Global hypoxic‐ischemic injury Small vessels ectasia, variable perivascular oedema, perivascular micro‐haemorrhages Endovascular microthrombi Microglial activation, especially in medulla oblongata Recent cerebral parietal infraction and microscopic cortical infarcts Oedema Right frontal lobe infarction Meningeal congestion Global hypoxic‐ischemic injury Small vessels ectasia, variable perivascular oedema, perivascular micro‐haemorrhages Endovascular microthrombi Sparse microglial activation, especially in medulla oblongata Ancient frontal lobe infarction (glial scar) and recent microscopic infarcts Left pyramidal tract atrophy Oedema Meningeal congestion Global hypoxic‐ischemic injury Small vessels ectasia, variable perivascular oedema, perivascular micro‐haemorrhages Endovascular microthrombi Recent microscopic infarcts Moderate meningeal chronic lymphocytic infiltration (composed of T‐lymphocytes, Cd3 and CD4 positive) Oedema Uncal herniation Meningeal congestion Global hypoxic‐ischemic injury Small vessels ectasia, variable perivascular oedema, perivascular micro‐haemorrhages Endovascular microthrombi Recent microscopic infarcts Oedema Uncal herniation Meningeal congestion Global hypoxic‐ischemic injury Small vessels ectasia, variable perivascular oedema, perivascular micro‐haemorrhages Endovascular microthrombi Recent microscopic infarcts Oedema Meningeal congestion Global hypoxic‐ischemic injury Small vessels ectasia, variable perivascular oedema, perivascular micro‐haemorrhages Endovascular microthrombi Recent microscopic infarcts Sparse microglial activation, especially in medulla oblongata Oedema Meningeal congestion Meningeal purulent accumulation Global hypoxic‐ischemic injury Small vessels ectasia, variable perivascular oedema, perivascular micro‐haemorrhages Endovascular microthrombi Recent microscopic infarcts Microglial activation, especially in medulla oblongata Initial feature of Acute purulent meningitis Oedema Meningeal congestion with focal blood extravasation Atherosclerosis Global hypoxic‐ischemic injury Small vessels ectasia, variable perivascular oedema, perivascular micro‐haemorrhages Endovascular microthrombi Focal leptomeningeal haemorrhage Recent parieto‐occipital lobe infarction and microscopic infarcts. Spinal cord Schwannoma Oedema Meningeal congestion Global hypoxic‐ischemic injury Small vessels ectasia, variable perivascular oedema, perivascular micro‐haemorrhages Endovascular microthrombi Recent microscopic infarcts, the largest in the para‐hippocampal region SARS‐CoV‐2 RNA was present in the olfactory nerve and brain tissue of one (of 10 tested) patients (case 1). In this patient olfactory bulb neurons, olfactory tract and brain tissue did not show any specific histological change suggestive of direct viral damage (Figure 1A). The SARS‐CoV‐2‐RNA positive case presented several comorbidities, had the shortest disease course (death occurred 6 days only after the symptoms onset) and showed viral involvement of kidney, liver and heart in addition to brain and lungs, thus suggesting hematogenous spread.
Figure 1

A: SARS‐CoV‐2 positive olfactory tract did not show any specific pathological features suggestive of viral damage (case 1). B: Microthrombi were seen in small intraperenchymal vessels located in the brain stem of SARS‐CoV‐2 positive case (case 1). C: Cortical microscopic ischemic areas in occipital cortex (case 4). D, E: Micro‐haemorrhages and rare haemosiderin laden macrophages were seen in small intraperenchymal vessels located in the brain stem of SARS‐CoV‐2 positive and negative cases (case 9). F: Very rare perivascular lymphocytes were present (case 4, medulla oblongata). Almost all lymphocytes were CD3+ (inset). G: Medulla oblongata showed diffuse GFAP positivity both in SARS‐CoV‐2 positive and negative cases (case 2). H: Gross examination of case 8, showing purulent accumulation on the leptomeningeal vault. I: in case 8, leptomeningeal vessels were enlarged and filled with septic thrombi, mainly composed of granulocytes

A: SARS‐CoV‐2 positive olfactory tract did not show any specific pathological features suggestive of viral damage (case 1). B: Microthrombi were seen in small intraperenchymal vessels located in the brain stem of SARS‐CoV‐2 positive case (case 1). C: Cortical microscopic ischemic areas in occipital cortex (case 4). D, E: Micro‐haemorrhages and rare haemosiderin laden macrophages were seen in small intraperenchymal vessels located in the brain stem of SARS‐CoV‐2 positive and negative cases (case 9). F: Very rare perivascular lymphocytes were present (case 4, medulla oblongata). Almost all lymphocytes were CD3+ (inset). G: Medulla oblongata showed diffuse GFAP positivity both in SARS‐CoV‐2 positive and negative cases (case 2). H: Gross examination of case 8, showing purulent accumulation on the leptomeningeal vault. I: in case 8, leptomeningeal vessels were enlarged and filled with septic thrombi, mainly composed of granulocytes On macroscopic examination, all cases presented an edematous brain surface with widened gyri, flattened surface, narrowed sulci and meningeal congestion. Brain weight ranged from 1300 to 1870 g. (mean 1560 g.). In two cases, bilateral uncal herniation was identified (cases 5, 6). Areas of cerebral infarction were present in three cases (cases 1, 2, 3). Meninges were grossly congested: purulent accumulation on the leptomeningeal vault was observed in case 8, whereas focal subarachnoid haemorrhage was identified in case 9. On histology, all cases presented intraparenchymal intravascular microthrombi (Figure 1B) with focal microscopic (usually 1–2 mm in size) cortical or deep‐seated (located in the basal ganglia and through the brainstem) recent infarcts (Figure 1C). Small blood vessels ectasia, perivascular edema, perivascular micro‐hemorrhages and scattered hemosiderin‐laden macrophages were also noticed (Figure 1D,E). Necrotic blood vessels or perivascular inflammation were not identified. Immunohistochemical analysis (CD20, CD3, CD4, CD8 and CD68) did not highlight lymphocytic or macrophage accumulation. Only case 4 showed a mild perivascular T‐lymphocytic infiltration CD3+ (Figure 1F) more evident in the leptomeninges. Luxol fast blue and immunohistochemical staining for neurofilaments demonstrated only a slight perivascular myelin reduction with no clear evidence of axonal injury. Activation of microglia and astrocytes was noticed mainly in the brainstem (Figure 1G). No microglial nodules or evidence of neuronophagia were present. Intravascular microthrombi and multiple infarcts are in keeping with the hypercoagulable state of SARS‐CoV‐2‐infected patients (1) leading to large and small vessels thrombosis. Our data, together with previously published data, indicate that most likely the same pathogenetic events may occur in CNS SARS‐CoV‐2‐related injuries. Ischemic red neurons were present through the hippocampal CA1 region, the parahippocampal region (case 10) and the cerebellar Purkinje cells, consistent with global ischemic injury. Also the brainstem showed, in addition to microthrombi and ischemic damage, reactive gliosis and microglial activation most likely due to preterminal hypoxic–ischemic injury. These data, consistent with those of Jensen et al (4), Kantonen et al (5) and Solomon et al (8), suggest that the hypoxic‐ischemic general condition, related to the respiratory failure, may indeed be worsened by the consequent brainstem damage appearing as a final event (6). Bacterial superinfection was histologically suspected in two cases (cases 8, 9): leptomeningeal thrombi composed of dense fibrin with neutrophils were detected (Figure 1H,I). In these patients, Pseudomonas aeruginosa, Candida albicans, Staphylococcus capitis, Staphylococcus aureus and Methicillin‐resistant Staphylococcus aureus (MRSA) were, respectively, isolated in bronchoalveolar lavage fluid and from blood cultures. Infective meningoencephalitis has been well‐documented as a complication during SARS‐CoV‐2 infection (7). In the remaining cases, leptomeningeal vascular congestions was seen. The leptomeningeal vascular alterations detected in the present cases, are consistent with the findings described by Helms et al who detected, on Magnetic Resonance Imaging, leptomeningeal spaces enhancement in 8/13 patients and bilateral frontal hypoperfusion in 11 patients (3). Furthermore, in Helms et al series, three asymptomatic patients presented small acute or subacute ischemic strokes (3). The present study has some limitations, including the small sample size and the absence of pre‐mortem specific neurologic symptoms. In addition, autopsies were not consecutive, but performed on cases that experienced an unexpectedly fatal course. Therefore, data shown here may not reflect the pathologic involvement of all SARS‐CoV‐2‐infected patients. Nevertheless, in spite of these limitations, this study supports the hypothesis formulated by Romoli et al (9) that SARS‐CoV‐2‐related brain injury maybe the consequence of several pathogenetic mechanisms in addition to direct viral damage. Furthermore, brain lesions were present even in the absence of specific neurological symptoms. Therefore, it is possible that brain involvement is an underestimated feature in SARS‐CoV‐2‐infected patients.

Conflict of Interest

The author declares that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Data Availability Statement

All the data supporting the findings of this study (histologic specimens, clinical data) are available from the corresponding author on request. All the data that have been cited in this paper are openly available in PubMed® at https://pubmed.ncbi.nlm.nih.gov/. Supplementary Material Click here for additional data file.
  21 in total

1.  Neuropathology of COVID-19 (neuro-COVID): clinicopathological update.

Authors:  Jerry J Lou; Mehrnaz Movassaghi; Dominique Gordy; Madeline G Olson; Ting Zhang; Maya S Khurana; Zesheng Chen; Mari Perez-Rosendahl; Samasuk Thammachantha; Elyse J Singer; Shino D Magaki; Harry V Vinters; William H Yong
Journal:  Free Neuropathol       Date:  2021-01-18

Review 2.  Role of SARS-CoV-2 in Modifying Neurodegenerative Processes in Parkinson's Disease: A Narrative Review.

Authors:  Jeremy M Morowitz; Kaylyn B Pogson; Daniel A Roque; Frank C Church
Journal:  Brain Sci       Date:  2022-04-22

3.  COVID-19 and the Brain: The Neuropathological Italian Experience on 33 Adult Autopsies.

Authors:  Viscardo P Fabbri; Mattia Riefolo; Tiziana Lazzarotto; Liliana Gabrielli; Giovanna Cenacchi; Carmine Gallo; Raffaele Aspide; Guido Frascaroli; Rocco Liguori; Raffaele Lodi; Caterina Tonon; Antonietta D'Errico; Maria Pia Foschini
Journal:  Biomolecules       Date:  2022-04-25

4.  Age-Associated Neurological Complications of COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Brianne N Sullivan; Tracy Fischer
Journal:  Front Aging Neurosci       Date:  2021-08-02       Impact factor: 5.750

5.  Microgliosis and neuronal proteinopathy in brain persist beyond viral clearance in SARS-CoV-2 hamster model.

Authors:  Christopher Käufer; Cara S Schreiber; Anna-Sophia Hartke; Ivo Denden; Stephanie Stanelle-Bertram; Sebastian Beck; Nancy Mounogou Kouassi; Georg Beythien; Kathrin Becker; Tom Schreiner; Berfin Schaumburg; Andreas Beineke; Wolfgang Baumgärtner; Gülsah Gabriel; Franziska Richter
Journal:  EBioMedicine       Date:  2022-04-16       Impact factor: 11.205

6.  Neuropathologic findings of patients with COVID-19: a systematic review.

Authors:  Azalea T Pajo; Adrian I Espiritu; Almira Doreen Abigail O Apor; Roland Dominic G Jamora
Journal:  Neurol Sci       Date:  2021-01-22       Impact factor: 3.830

Review 7.  Neurological update: COVID-19.

Authors:  A L Ren; R J Digby; E J Needham
Journal:  J Neurol       Date:  2021-04-30       Impact factor: 4.849

8.  Brain dysfunction in COVID-19 and CAR-T therapy: cytokine storm-associated encephalopathy.

Authors:  Umberto Pensato; Lorenzo Muccioli; Ilaria Cani; Damir Janigro; Pier Luigi Zinzani; Maria Guarino; Pietro Cortelli; Francesca Bisulli
Journal:  Ann Clin Transl Neurol       Date:  2021-03-29       Impact factor: 4.511

Review 9.  What can we learn from brain autopsies in COVID-19?

Authors:  Shibani S Mukerji; Isaac H Solomon
Journal:  Neurosci Lett       Date:  2020-11-25       Impact factor: 3.046

10.  Is COVID-19 a Perfect Storm for Parkinson's Disease?

Authors:  Patrik Brundin; Avindra Nath; J David Beckham
Journal:  Trends Neurosci       Date:  2020-10-21       Impact factor: 13.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.